Rare diseases

Explore drug discovery landscapes

Rare hematologic diseases

Rare developmental defect during embryogenesis

Rare skin diseases

Rare odontologic diseases

Rare cardiac diseases

Rare infectious diseases

Rare ophthalmic disorders

Rare gastroenterologic diseases

Rare renal diseases

Rare endocrine diseases

Rare immune diseases

Rare hepatic diseases

Rare otorhinolaryngologic disease

Rare gynecologic or obstetric diseases

Rare respiratory disease

Rare infertility

Rare genetic diseases

Rare circulatory system diseases

Rare abdominal surgical diseases

Rare maxillo-facial surgical disease

Rare urogenital diseases

Rare disorder due to toxic effects

Rare surgical thoracic diseases

Rare surgical cardiac diseases

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.